BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zeposia (ozanimod) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zeposia (ozanimod)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06862960-14@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zeposia (ozanimod): Phase 2 readout est. (NCT06862960)
DESCRIPTION:Zeposia (ozanimod)\, phase 2.\nStudy: Ozanimod in Patients With
  Alzheimer's Disease\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ozanimod#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06862960
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06529406-14@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Zeposia (ozanimod): Phase 4 readout est. (NCT06529406)
DESCRIPTION:Zeposia (ozanimod)\, phase 4\, Multiple Sclerosis.\nStudy: Pros
 pective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod\nEst
 imated primary completion: 1 August 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ozanimod#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06529406
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06396039-14@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Zeposia (ozanimod): Phase 4 readout est. (NCT06396039)
DESCRIPTION:Zeposia (ozanimod)\, phase 4\, Multiple Sclerosis.\nStudy: A St
 udy to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults W
 ith Relapsing Multiple Sclerosis\nEstimated primary completion: 29 Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ozanimod#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06396039
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408259-14@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20310411
DTEND;VALUE=DATE:20310412
SUMMARY:Zeposia (ozanimod): Phase 3 readout est. (NCT06408259)
DESCRIPTION:Zeposia (ozanimod)\, phase 3\, Multiple Sclerosis.\nStudy: Stud
 y to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingoli
 mod in Children and Adolescents With Relapsing Remitting Multiple Sclerosi
 s\nEstimated primary completion: 11 April 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ozanimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06408259
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076175-14@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20320712
DTEND;VALUE=DATE:20320713
SUMMARY:Zeposia (ozanimod): Phase 2/3 readout est. (NCT05076175)
DESCRIPTION:Zeposia (ozanimod)\, phase 2/3\, Ulcerative Colitis.\nStudy: A 
 Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With
  Moderate to Severe Active Ulcerative Colitis\nEstimated primary completio
 n: 12 July 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ozan
 imod#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05076175
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
